Randomized controlled crossover study of the effect of a highly beta-glucan-enriched XXXX on @entity65 risk factors in mildly hypercholesterolemic @entity1 .

@entity1 @entity2247 @entity6 @entity1674 @entity413 @entity65 @entity165
BACKGROUND: Soluble-fiber beta-glucan derived from oats can reduce @entity65 ( @entity65 ) risk through reductions in total and LDL @entity165 . @entity2247 -derived beta-glucan may also improve serum @entity165 , but large quantities are required for clinical significance. OBJECTIVE: This trial investigated whether a beta-glucan-enriched form of @entity2247 can favorably modify @entity165 and other markers of @entity65 and @entity6 risk. DESIGN: Eighteen mildly hyperlipidemic ( +/- SD: 4.0 +/- 0.6 mmol LDL @entity165 /L) @entity1 with a mean (+/- SD) body mass index (in kg/m(2)) of 27.4 +/- 4.6 were randomly assigned in this single-blind, 2 x 4-wk trial to either the treatment arm [8.1-11.9 g beta-glucan/d (scaled to body weight)] or the control arm (isoenergetic dose of 6.5-9.2 g @entity413 /d). After a washout period of 4 wk, dietary regimens were crossed over. The trial took place in a long-stay metabolic facility, and all foods were provided (38% of energy from fat). Fasted blood samples were collected on days 0, 1, 7, 14, 21, 28, and 29 in both study arms. An oral- @entity413 -tolerance test was carried out on days 0 and 29. RESULTS: There was no significant change (Delta) in total (Delta = -0.08 mmol/L, -1.3%), LDL (Delta = -0.15 mmol/L, -3.8%), or HDL (Delta = 0 mmol/L) @entity165 or in @entity1674 (Delta = 0.18 mmol/L), fasting @entity413 (Delta = -0.05 mmol/L), or postprandial @entity413 when analyzed between treatments (P > 0.05; ANOVA). CONCLUSION: The effect of beta-glucan-enriched @entity2247 on lipid profile was highly variable between subjects, and there was no evidence of a clinically significant improvement in @entity65 risk across this group of mildly hyperlipidemic @entity1 .
